Emerging Research of RNAi-Based Therapies for FCS

Author(s):

Kausik K. Ray, MD, MRCP: From the Department of Public Health,Gerald Watts, MD, PhD

Panelists discuss how early diagnosis and intervention in familial chylomicronemia syndrome (FCS) are crucial for preventing cardiovascular and metabolic complications, emphasizing the key role clinicians play in initiating timely and effective treatment strategies.

EP: 1.Familial Chylomicronemia Syndrome: Diagnosis, Genetic Factors, and Long-Term Health Implications

EP: 2.Quality of Life and Diagnostic Considerations for FCS

EP: 3.PALISADE Study: Plozasiran’s Efficacy and Potential in Reducing Triglycerides and Pancreatitis

Now Viewing

EP: 4.Emerging Research of RNAi-Based Therapies for FCS

EP: 5.Reflections on Plozasiran Trial Data and Future Potential

EP: 6.SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3

EP: 7.Novel Research Frontiers on the Management of FCS

Video content above is prompted by the following:

What are the benefits of early diagnosis and intervention in familial chylomicronemia syndrome for preventing cardiovascular and metabolic complications, and what role do clinicians play in this process?